KRYS
Krystal Biotech Inc. Healthcare - Biotechnology Investor Relations →
Krystal Biotech Inc. (KRYS) closed at $251.68 as of 2026-03-20, trading 76.8% above its 200-week moving average of $142.36. The stock moved further from the line this week, up from 74.9% last week. The 14-week RSI sits at 53, indicating neutral momentum.
Trading volume is running at 1.7x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.11 ratio) is neutral — neither side is clearly dominating.
Over the past 395 weeks of data, KRYS has crossed below its 200-week moving average 1 time. On average, these episodes lasted 1 weeks. Historically, investors who bought KRYS at the start of these episodes saw an average one-year return of +97.7%.
With a market cap of $7.4 billion, KRYS is a mid-cap stock. The company generates a free cash flow yield of 1.3%. Return on equity stands at 18.9%, a solid level. The stock trades at 6.0x book value.
Share count has increased 13.3% over three years, indicating dilution. KRYS passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow.
Over the past 7.7 years, a hypothetical investment of $100 in KRYS would have grown to $1531, compared to $252 for the S&P 500. That represents an annualized return of 42.7% vs 12.8% for the index — confirming KRYS as a market-beating investment and the kind of quality company where buying during 200-week moving average touches has historically been rewarded.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: KRYS vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After KRYS Crosses Below the Line?
Across 1 historical episodes, buying KRYS when it crossed below its 200-week moving average produced an average return of +14.0% after 12 months (median +14.0%), compared to -9.0% for the S&P 500 over the same periods. 100% of those episodes were profitable after one year. After 24 months, the average return was +56.0% vs +3.0% for the index.
Each line shows $100 invested at the moment KRYS crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
KRYS has crossed below its 200-week MA 1 time with an average 1-year return of +97.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Nov 2021 | Nov 2021 | 1 | 3.7% | +97.7% | +532.2% |
| Average | 1 | — | +97.7% | — |
Frequently Asked Questions
Is KRYS below its 200-week moving average?
No. Krystal Biotech Inc. (KRYS) is currently 76.8% above its 200-week moving average of $142.36. It would need to fall to $142.36 to cross below the line.
What is KRYS's 200-week moving average price?
Krystal Biotech Inc.'s 200-week moving average is $142.36 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when KRYS drops below its 200-week moving average?
KRYS has crossed below its 200-week moving average 1 time in our data. On average, buying at that moment produced a one-year return of +97.7%. These dips have historically been decent entry points. These episodes lasted 1 weeks on average.
Is KRYS a good value right now?
Here's what our data says about KRYS as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 53. Free cash flow yield is 1.3%. Return on equity is 18.9%. Price-to-book is 6.0x. This is not a buy or sell recommendation — always do your own research.
How does KRYS compare to the S&P 500?
Over the past 7.7 years, $100 invested in KRYS would have grown to $1531, compared to $252 for the S&P 500. That's 42.7% annualized vs 12.8% for the index. KRYS has outperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20